Codon 129 polymorphism of prion protein gene in is not a risk factor for Alzheimer's disease
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC ARQUIVOS NEURO- PSIQUIATRIA
Autores
LANDEMBERGER, Michele Christine
BAHIA, Valeria Santoro
MARTINS, Vilma Regina
Citação
ARQUIVOS DE NEURO-PSIQUIATRIA, v.71, n.7, p.423-427, 2013
Resumo
Interaction of prion protein and amyloid-b oligomers has been demonstrated recently. Homozygosity at prion protein gene (PRNP) codon 129 is associated with higher risk for Creutzfeldt-Jakob disease. This polymorphism has been addressed as a possible risk factor in Alzheimer disease (AD). Objective:To describe the association between codon 129 polymorphisms and AD. Methods: We investigated the association of codon 129 polymorphism of PRNP in 99 AD patients and 111 controls, and the association between this polymorphism and cognitive performance. Other polymorphisms of PRNP and additive effect of apolipoprotein E gene (ApoE) were evaluated. Results: Codon 129 genotype distribution in AD 45.5% methionine (MM), 42.2% methionine valine (MV), 12.1% valine (VV); and 39.6% MM, 50.5% MV, 9.9% VV among controls (p>0.05). There were no differences of cognitive performance concerning codon 129. Stratification according to ApoE genotype did not reveal difference between groups. Conclusion: Codon 129 polymorphism is not a risk factor for AD in Brazilian patients.
Palavras-chave
prion protein gene, Alzheimer's disease, polymorphism, codon 129, cognitive performance, apolipoprotein E gene
Referências
- Bahia VS, 2008, ALZ DIS ASSOC DIS, V22, P61, DOI 10.1097/WAD.0b013e31815a9da7
- Berr C, 1998, NEUROLOGY, V51, P734
- Bishop MT, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-146
- Brandel JP, 2000, NEUROLOGY, V54, P1095
- Calella AM, 2010, EMBO MOL MED, V2, P306
- Caler O, 2011, PLOS ONE, V6, P22090
- Casadei VM, 2001, J NEUROL NEUROSUR PS, V71, P278
- Castro RMRPS, 2004, J NEUROSCI METH, V139, P263, DOI 10.1016/j.jneumeth.2004.05.001
- Combarros O, 2000, NEUROLOGY, V55, P593
- Croes EA, 2003, ANN NEUROL, V54, P275, DOI 10.1002/ana.10658
- Del Bo R, 2006, NEUROBIOL AGING, V27, P770
- de Paula EV, 2005, EUR J EPIDEMIOL, V20, P593, DOI 10.1007/s10654-005-7455-5
- Dermaut B, 2003, ANN NEUROL, V53, P409, DOI 10.1002/ana.10507
- Gacia M, 2006, J NEURAL TRANSM, V113, P1747, DOI 10.1007/s00702-006-0540-4
- Gimbel DA, 2010, J NEUROSCI, V30, P6367, DOI 10.1523/JNEUROSCI.0395-10.2010
- Glatzel M, 2003, LANCET NEUROL, V2, P757, DOI 10.1016/S1474-4422(03)00588-X
- Golanska E, 2004, NEUROLOGY, V62, P313
- Gossrau G, 2006, J NEURAL TRANSM, V113, P331, DOI 10.1007/s00702-005-0329-x
- Herrera E, 2002, ALZ DIS ASSOC DIS, V16, P103, DOI 10.1097/01.WAD.0000020202.50697.df
- Jeong BH, 2004, J HUM GENET, V49, P319, DOI 10.1007/s10038-004-0150-7
- Jeong BH, 2007, EUR J NEUROL, V14, P621, DOI 10.1111/j.1468-1331.2007.01786.x
- Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761
- Li XH, 2005, ANN NEUROL, V58, P858, DOI 10.1002/ana.20646
- Ohkubo T, 2003, ANN NEUROL, V54, P553, DOI 10.1002/ana.10748
- Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613
- Poleggi A, 2008, EUR J NEUROL, V15, P173, DOI 10.1111/j.1468-1331.2007.02021.x
- Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363
- Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
- Riemenschneider M, 2004, NEUROLOGY, V63, P364
- Rujescu D, 2003, MOL PSYCHIATR, V8, P937, DOI 10.1038/sj.mp.4001327
- Scholz SW, 2006, NEUROSCI LETT, V395, P227, DOI 10.1016/j.neulet.2005.10.081
- STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977